Results 151 to 160 of about 36,083 (204)

RETRACTED: Cardiovascular and mortality outcomes of DPP-4 inhibitors vs. sulfonylureas as metformin add-on therapy in patients with type 2 diabetes: A systematic review and meta-analysis.

PLoS One
Hasan R, Chugaeva UY, Mohammadian M, Zamanifard S, Mohammadian-Hafshejani A.   +4 more
europepmc   +1 more source

Erratum: Efficacy and Safety of DPP-4 Inhibitors and Metformin Combinations in Type 2 Diabetes: A Systematic Literature Review and Network Meta-Analysis [Corrigendum]. [PDF]

Diabetes Metab Syndr Obes
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

DPP-4 inhibitors: pharmacological differences and their clinical implications

Expert Opinion on Drug Safety, 2014
Recently, incretin-based therapy was introduced for the treatment of type 2 diabetes (T2D). In particular, dipeptidyl peptidase-4 inhibitors (DPP-4i) (sitagliptin, vildagliptin, saxagliptin, linagliptin and alogliptin) play an increasing role in the management of T2D.An extensive literature search was performed to analyze the pharmacological ...
Ceriello A, SPORTIELLO, Liberata, RAFANIELLO, Concetta, ROSSI, Francesco   +3 more
openaire   +4 more sources

Novel DPP-4 Inhibitors Against Diabetes

Future Medicinal Chemistry, 2014
DPP-4 specifically degrades the incretin hormone GLP-1 and GIP, both of which are vital modulators of blood glucose homeostasis. Attributed to its potential biological function, DPP-4 inhibition has presently represented an attractive therapeutic strategy for treating diabetes and aroused a significant interest in the pharmaceutical industry.
Yang, Liu, Yongzhou, Hu
openaire   +2 more sources

DPP-4 inhibitors: focus on safety

Expert Opinion on Drug Safety, 2014
Dipeptidyl peptidase inhibitors (DPP-4-i) are highly selective inhibitors of the enzyme DPP-4. They act by increasing levels of incretin hormones, which have potent effects on insulin and glucagon release, gastric emptying, and satiety. Our goal is to review the safety issues related to DPP-4-i.This review is based upon a PubMed search of the ...
Sri Harsha, Tella, Marc S, Rendell
openaire   +2 more sources

DPP-4 Inhibitors in Clinical Practice

Postgraduate Medicine, 2009
Type 2 diabetes is a very common worldwide disorder, with major consequences for patients, society, and health care services. Good glycemic control is an important aspect of diabetes management because it has a significant impact on diabetes-related microvascular and possibly macrovascular complications.
Palalau, Anna I., Tahrani, Abd A., Piya, Milan K. (R19111), Barnett, Anthony   +3 more
openaire   +3 more sources

Wildagliptyna - wyjątkowy inhibitor DPP-4

Medycyna Faktów, 2022
Wildagliptyna jest jedynym lekiem z grupy inhibitorów DPP-4, który stosuje się 2 razy dziennie. Chociaż nie przeprowadzono badania poświęconego bezpieczeństwu sercowo-naczyniowemu stosowania tego leku, to licznie opublikowane metaanalizy oraz badania obserwacyjne jednoznacznie potwierdziły bezpieczeństwo wildagliptyny w tym zakresie.
openaire   +2 more sources

The Research Progress of DPP-4 Inhibitors

Mini-Reviews in Medicinal Chemistry, 2020
Diabetes mellitus (DM) is a metabolic disease, and diabetes patients have long-term higher blood sugar levels than standard. Most people with diabetes have complications that greatly affect their standard of living. Patients with type 2 DM occupy the vast majority of all diabetes patients.
Zhi-Gang, Sun, Zhi-Na, Li, Hai-Liang, Zhu   +2 more
openaire   +2 more sources

DPP-4 inhibitors

Insulin, 2007
Inhibition of dipeptidyl peptidase 4 (DPP-4) is a novel treatment for type-2 diabetes. DPP-4 inhibition prevents the inactivation of glucagon-like peptide 1 (GLP-1), which increases levels of active GLP-1. This increases insulin secretion and reduces glucagon secretion, thereby lowering glucose levels.
openaire   +2 more sources